| Literature DB >> 21943294 |
Michael Schaub1, Robin Sullivan, Lars Stark.
Abstract
BACKGROUND: Cocaine use has increased in most European countries, including Switzerland, and many states worldwide. The international literature has described treatment models that target the general population. In addition to supplying informative measures at the level of primary and secondary prevention, the literature also offers web-based self-help tools for problematic substance users, which is in line with tertiary prevention. Such programs, however, have been primarily tested on individuals with problematic alcohol and cannabis consumption, but not on cocaine-dependent individuals. METHODS/Entities:
Mesh:
Year: 2011 PMID: 21943294 PMCID: PMC3187741 DOI: 10.1186/1471-244X-11-153
Source DB: PubMed Journal: BMC Psychiatry ISSN: 1471-244X Impact factor: 3.630
Inclusion and exclusion criteria and reasoning
| Reasoning | |
|---|---|
| - Minimal age of 18 years | To ensure a minimal age of participation |
| - Cocaine use > 2 occasions in the last 30 days | To include occasional users in order to provide extended study validity |
| - Participation in other psycho-social or pharmacological treatments for the reduction/cessation of cocaine use | To avoid confounding of treatment effects |
| - Opioid use in the last 30 days (exception: substitution maintenance treatment for opioid dependence without heroin use in the last 30 days) | To avoid confounding of drug effects |
| - Ever been in treatment for cardiovascular problems or apoplexy | To avoid subjects with these problems entering the study |
| - BDI-V score > 45 | To avoid subjects with serious symptoms of depression entering the study |
Measurements and instruments
| Assessments/instruments | Baseline | 3 weeks | 6 weeks | 6-month follow up |
|---|---|---|---|---|
| Socio-demographics | x | |||
| Previous psychiatric and somatic treatments | x | |||
| SDS | x | x | x | x |
| CCQ-B | x | x | x | x |
| FDA | x | x | x | x |
| BDI-V | x | x | x |
Figure 1Trial flowchart. This figure provides an overview of the participant flow for this trial.